Approval for Vertex Pharmaceutical's sickle cell treatment using CRISPR technology has brought use of the gene-editing therapy to a "collision point," according to Professor Jacob Sherkow. Speaking to the MIT Technology Review, Sherkow explained how the patent on editing human cells using CRISPR is owned by the Broad Institute of MIT and Harvard, not Vertex, which will almost certainly result in a lawsuit. With a potential market in the tens of billions, Sherkow believes a lawsuit is inevitable.
Read more from MIT Technology Review.